FIELD: chemico-pharmaceutical industry.
SUBSTANCE: the suggested pharmaceutical composition contains 2-20% loxoprofen or its pharmaceutically acceptable salt as an active ingredient in water for injections in combination with stabilizing agent or solubilizing additive.
EFFECT: increased bioavailability and efficiency.
7 cl, 1 dwg, 14 ex, 18 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW SALVIANOLIC ACID COMPOUND T, PREPARATION METHOD THEREFOR AND USE THEREOF | 2014 |
|
RU2668955C2 |
| NOVEL OPTICALLY ACTIVE PHENYLETHANOLAMINE COMPOUNDS AND SYNTHESIS METHOD THEREOF | 2007 |
|
RU2416597C2 |
| KERATIN BD-4, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF | 2020 |
|
RU2824893C1 |
| EPOTILONE PHARMACEUTICAL DOSED FORMULATION FOR ORAL ADMINISTRATION | 2002 |
|
RU2291695C2 |
| OSTEOARTHRITIS TREATMENT COMPOSITION COMPRISING HYDROPHILISED SULPHASALASINE AND HYALURONIC ACID, AND A METHOD OF PRODUCING SAID COMPOSITION | 2016 |
|
RU2712168C1 |
| GLYCOSAMINOGLYCANES APPLIED FOR TREATING SENILE FEEBLE-MINDEDNESS | 2000 |
|
RU2248800C2 |
| NEW COMPOUNDS | 2000 |
|
RU2258703C2 |
| NOVEL EFFICIENT INHIBITOR OF KINASE 4, ASSOCIATED WITH INTERLEUKIN-1 (IRAK4) | 2015 |
|
RU2613973C1 |
| USE OF MITOXANTHRONE TO OBTAIN A MEDICINAL PRODUCT FOR DIAGNOSTICS AND TREATMENT OF DISEASE ASSOCIATED WITH THYROIDECTOMY | 2021 |
|
RU2817199C1 |
| MEDICAL USE OF ANEMOSIDE B4 AGAINST ACUTE GOUTY ARTHRITIS | 2018 |
|
RU2784896C2 |
